Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the "Note") with Mr. Hung-Wen (Howard) Chen, the Company's Chairman and Chief Executive Officer, on March 30, 2026.

The $2.0 million in proceeds from the Note are intended to provide the Company with necessary working capital to support clinical development programs and general corporate operations.

The Note is an unsecured obligation of the Company and carries a 0% interest rate. Under the terms of the agreement, the principal amount will automatically convert into equity securities of the Company upon the closing of a subsequent equity financing with aggregate gross proceeds of at least $10.0 million. The conversion price will be calculated at a 20% discount to the lowest per-share price issued to investors in such financing.